FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study

被引：7

作者：

Torregrosa, Cecile ^{[1
]}

Pernot, Simon ^{[2
]}

Vaflard, Pauline ^{[3
]}

Perret, Audrey ^{[4
]}

Tournigand, Christophe ^{[5
]}

Randrian, Violaine ^{[6
]}

Doat, Solene ^{[7
]}

Neuzillet, Cindy ^{[8
]}

Moulin, Valerie ^{[9
]}

Stouvenot, Morgane ^{[10
]}

Roth, Gael ^{[11
]}

Darbas, Tiffany ^{[12
]}

Auberger, Benjamin ^{[13
]}

Godet, Tiphaine ^{[14
]}

Jaffrelot, Marion ^{[15
]}

Lambert, Aurelien ^{[16
]}

Dubreuil, Olivier ^{[17
]}

Gluszak, Cassandre ^{[18
]}

Bernard-Tessier, Alice ^{[19
]}

Turpin, Anthony ^{[20
]}

Palmieri, Lola-Jade ^{[21
]}

Bouche, Olivier ^{[22
]}

Goujon, Gael ^{[23
]}

Lecomte, Thierry ^{[24
,25
]}

Sefrioui, David ^{[26
,27
]}

Locher, Christophe ^{[28
]}

Grados, Lucien ^{[29
]}

Gignoux, Pauline ^{[30
]}

Trager, Stephanie ^{[31
]}

Nassif, Elise ^{[32
]}

Saint, Angelique ^{[33
]}

Hammel, Pascal ^{[34
]}

Lecaille, Cedric ^{[35
]}

Bureau, Mathilde ^{[36
]}

Perrier, Marine ^{[22
]}

Botsen, Damien ^{[22
]}

Bourgeois, Vincent ^{[37
]}

Taieb, Julien ^{[1
]}

Auclin, Edouard ^{[1
]}

机构：

[1] Univ Paris, Hop Europeen Georges Pompidou, AP HP, Gastrointestinal Oncol Dept, Paris, France

[2] Bergonie Inst, Med Oncol, Bordeaux, France

[3] Curie Inst, Med Oncol Dept, Paris, France

[4] Gustave Roussy Canc Inst, Dept Canc Med, Villejuif, France

[5] Paris Est Creteil Univ, Henri Mondor Hosp, Assistance Publ Hop Paris, Med Oncol,INSERM, Creteil, France

[6] Univ Hosp Ctr Poitiers, Hepatol & Gastroenterol Dept, Poitiers, France

[7] Pitie Salpetriere Univ Hosp, Assistance Publ Hop Paris, Digest Oncol Dept, Paris, France

[8] Versailles St Quentin Paris Saclay Univ, Curie Inst, Med Oncol Dept, Paris, France

[9] Hosp La Rochelle, Oncol Dept, La Rochelle, France

[10] Univ Hosp Ctr Besancon, Dept Oncol, Besancon, France

[11] Univ Hosp Ctr Grenoble, Hepatogastroenterol & Digest Oncol Unit, Grenoble, France

[12] Univ Hosp Ctr Limoges, Oncol Dept, Limoges, France

[13] Univ Hosp Ctr Brest, Oncol Dept, Brest, France

[14] Univ Hosp Ctr Angers, Gastroenterol & Digest Oncol Dept, Angers, France

[15] Univ Hosp Ctr Toulouse, Digest Oncol Dept, Toulouse, France

[16] Inst Cancerol Lorraine, Med Oncol Dept, Nancy, France

[17] Diaconesses Croix St Simon Hosp, Med Oncol Dept, Paris, France

[18] Inst Cancerol Ouest, Med Oncol Dept, Angers, France

[19] St Antoine Hosp, AP HP, Gastroenterol & Digest Oncol Dept, Paris, France

[20] Univ Lille, Lille Univ Hosp, Dept Med Oncol, CNRS UMR9020,Inserm UMR S 1277 Canther Canc Heter, Lille, France

[21] Cochin Hosp, AP HP, Gastroenterol & Digest Oncol Dept, Paris, France

[22] Univ Hosp Ctr Reims, Oncol Dept, Reims, France

[23] Hop Xavier Bichat, Gastroenterol & Digest Oncol Dept, Paris, France

[24] Univ Tours, Tours Univ Hosp, Dept Hepatogastroenterol & Digest Oncol, Tours, France

[25] Univ Tours, INSERM U1069 Nutr Croissance & Canc, Tours, France

[26] Normandie Univ, Rouen Univ Hosp, Normandy Ctr Genom & Personalized Med, UNIROUEN,Inserm U1245,IRON Grp, Rouen, France

[27] Normandie Univ, Dept Hepatogastroenterol, UNIROUEN, Inserm U1245,IRON Grp,Rouen Univ Hosp, Rouen, France

[28] Meaux Hosp, Gastroenterol & Digest Oncol Dept, Meaux, Seine & Marne, France

[29] Univ Hosp Ctr Amiens, Gastroenterol & Digest Oncol Dept, Amiens, France

[30] Univ Hosp Ctr Martinique, Oncol Dept, Fort De France, Martinique, France

[31] Clin Stains, Med Oncol Dept, Stains, France

[32] Leon Berard Inst, Oncol Dept, Lyon, France

[33] Antoine Lacassagne Ctr, Med Oncol Dept, Nice, France

[34] Univ Paris Saclay, Hosp Paul Brousse, AP HP, Digest & Med Oncol Dept, Villejuif, France

[35] Polyclin Bordeaux Nord Aquitaine, Gastroenterol Dept, Bordeaux, France

[36] Univ Hosp Ctr Nantes, Digest Oncol Dept, Nantes, France

[37] Boulogne Sur Mer Hosp, Gastroenterol & Digest Oncol Dept, Boulogne Sur Mer, France

来源：

INTERNATIONAL JOURNAL OF CANCER | 2022年 / 151卷 / 11期

关键词：

aflibercept; bevacizumab; chemotherapy; metastatic colorectal cancer; RANDOMIZED-TRIAL; 1ST-LINE THERAPY; OXALIPLATIN; FLUOROURACIL; COMBINATION; LEUCOVORIN; ANGIOGENESIS; IRINOTECAN; IMPACT;

D O I：

10.1002/ijc.34166

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

After failure of first line FOLFOX-bevacizumab for metastatic colorectal cancer (mCRC), adding either bevacizumab or aflibercept to second-line FOLFIRI increases survival compared to FOLFIRI alone. In this French retrospective multicentre cohort, we included patients with a mCRC treated with either FOLFIRI-aflibercept or FOLFIRI-bevacizumab. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival (PFS), disease control rate (DCR: CR + PR + SD) and safety. We included 681 patients from 36 centers, 326 and 355 in the aflibercept and bevacizumab groups, respectively. Median age was 64.2 years and 45.2% of patients were men. Most patients had RAS-mutated tumors (80.8%) and synchronous metastases (85.7%). After a median follow up of 31.2 months, median OS was 13.0 months (95% CI: 11.3-14.7) and 10.4 months (95% CI: 8.8-11.4) in the bevacizumab and aflibercept groups, respectively (P < .0001). Median PFS was 6.0 months (95% CI: 5.4-6.5) and 5.1 months (95% CI: 4.3-5.6) (P < .0001). After adjustment on age, PS, PFS of first line, primary tumor resection, metastasis location and RAS/BRAF status, bevacizumab was still associated with better OS (HR: 0.71, 95% CI: 0.59-0.86, P = .0003). FOLFIRI-bevacizumab combination was associated with longer OS and PFS, and a better tolerability, as compared to FOLFIRI-aflibercept after progression on FOLFOX-bevacizumab.

引用

页码：1978 / 1988

页数：11

共 50 条

[1] Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study
Sekmek, Serhat
Ozsan celebi, Sema Nur
Bayram, Dogan
Erol, Cihan
Kos, Fahriye Tugba
Sendur, Mehmet Ali Nahit
Altintas, Yunus Emre
Tuylu, Tugba
Yildirim, Sedat
Biter, Sedat
Kidi, Mehmet Mutlu
Bayram, Ertugrul
Majidova, Nargiz
Bayoglu, Ibrahim Vedat
Atak, Mehmetcan
Baskurt, Kadriye
Akbas, Sinem
Alkan, Ali
Bayramgil, Ayberk
Aslan, Ferit
Sahin, Elif
Balcik, Onur Yazdan
Bayhan, Ahmet Ziya
Saray, Seray
Arpaci, Erkan
Ergun, Yakup
SCIENTIFIC REPORTS, 2024, 14 (01):
[2] FOLFOXIRI Plus Bevacizumab Versus FOLFOX/FOLFIRI Plus Bevacizumab for Metastatic Colorectal Cancer: An Updated Meta-Analysis
Muhibullah, Fnu
Shafique, Nouman
Khakwani, Anum
Qadeer, Abdul
Bajwa, Shammas Farooq
Ehsan, Amna
Aiman, Wajeeha
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S175 - S176
[3] Predicting benefit from FOLFOXIRI plus bevacizumab versus FOLFOX/FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer
Bond, M. J. G.
van Smeden, M.
Degeling, K.
Cremolini, C.
Schmoll, H. J. E-V.
Rossini, D.
Ibach, S.
Koopman, M.
Punt, C. J. A.
May, A. M.
Kwakman, J. J.
ANNALS OF ONCOLOGY, 2023, 34 : S438 - S438
[4] A phase two trial evaluating FOLFIRI plus aflibercept after failure of FOLFOXIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer
Ando, Koji
Satake, Hironaga
Shimokawa, Mototsugu
Yasui, Hisateru
Negoro, Yuji
Kinjo, Tatsuya
Kizaki, Junya
Baba, Kenji
Orita, Hiroyuki
Hirata, Keiji
Sakamoto, Sanae
Makiyama, Akitaka
Saeki, Hiroshi
Tsuji, Akihito
Baba, Hideo
Oki, Eiji
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (03) : 514 - 523
[5] Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX-Bevacizumab or FOLFIRI-Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study
Bendell, Johanna C.
Beikaii-Saab, Tanios S.
Cohn, Allen L.
Hurwitz, Herbert I.
Kozloff, Mark
Tezcan, Haluk
Roach, Nancy
Mun, Yong
Fish, Susan
Flick, E. Dawn
Dalal, Darshan
Grothey, Axel
ONCOLOGIST, 2012, 17 (12): : 1486 - 1495
[6] Retrospective comparison efficacy and toxicity FOLFIRI plus aflibercept or bevacizumab in patients with metastatic colorectal cancer: Results of the multicenter observational study
Fedyanin, M.
Chubenko, V.
Belonogov, A.
Beluhin, S.
Vladimirova, L.
Zhabina, A.
Kudryavtseva, A.
Moiseenko, F.
Khasanova, A.
Musaeva, H.
Novikova, O.
Stradaeva, I.
Mukhametshina, G.
Orlova, R.
Micshenko, A.
Popova, I.
Lyadova, M.
Popova, A.
Bolotina, L.
Kertiev, B.
Kuzmina, E.
Tjulandin, S.
ANNALS OF ONCOLOGY, 2020, 31 : S184 - S185
[7] Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
Astrid Lièvre
Emmanuelle Samalin
Emmanuel Mitry
Eric Assenat
Christine Boyer-Gestin
Céline Lepère
Jean-Baptiste Bachet
Fabienne Portales
Jean-Nicolas Vaillant
Marc Ychou
Philippe Rougier
BMC Cancer, 9
[8] Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
Lievre, Astrid
Samalin, Emmanuelle
Mitry, Emmanuel
Assenat, Eric
Boyer-Gestin, Christine
Lepere, Celine
Bachet, Jean-Baptiste
Portales, Fabienne
Vaillant, Jean-Nicolas
Ychou, Marc
Rougier, Philippe
BMC CANCER, 2009, 9 : 347
[9] What is the optimal duration of folfox-bevacizumab in metastatic colorectal cancer (mCRC)?
Rahal, M.
Hassan, E.
Shakir, S.
Meshikhes, M.
Ramadan, R.
El hadi, S. M.
Al mulla, A.
Al Manaa, A.
Abdelwarith, A.
Al Faraj, A.
ANNALS OF ONCOLOGY, 2008, 19 : 38 - 38
[10] Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe).
Wainberg, Zev A.
Boccia, Ralph V.
Strickler, John H.
Moehler, Markus H.
Sirard, Cynthia A.
Walsh, Erin K.
Parker, Elizabeth C.
Lee, Keun-Wook
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS275 - TPS275

← 1 2 3 4 5 →